There are several reports that mTOR activity is increased and autophagy is inhibited in HCC patients (15%–41%) which are associated with tumor cell survival, suggesting targeted mTOR pathway inhibition as a therapeutic option for HCC.151, 165. This evidence concerns the gene MTOR and neoplasm.